Xiu-xuan Sun
Xi'an, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
Journal: Signal transduction and targeted therapy
Published: November 01, 2024
Di-methylation of CD147-K234 Promotes the Progression of NSCLC by Enhancing Lactate Export.
Journal: Cell metabolism
Published: June 07, 2023
Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity.
Journal: Science (New York, N.Y.)
Published: March 17, 2023
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.
Journal: Signal transduction and targeted therapy
Published: November 11, 2022
CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis.
Journal: Signal transduction and targeted therapy
Published: March 18, 2022
PDGFA-associated protein 1 is a novel target of c-Myc and contributes to colorectal cancer initiation and progression.
Journal: Cancer communications (London, England)
Published: January 21, 2022
CD147 supports paclitaxel resistance via interacting with RanBP1.
Journal: Oncogene
Published: June 29, 2021
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
Journal: Signal transduction and targeted therapy
Published: February 08, 2021
CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression.
Journal: Signal transduction and targeted therapy
Published: January 10, 2021
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.
Journal: Signal transduction and targeted therapy
Published: November 02, 2020
Last Updated: 09/26/2026